NASDAQ:MDWD MediWound - MDWD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MediWound Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $13.73 -0.44 (-3.11%) (As of 01/30/2023 04:32 PM ET) Add Compare Share Share Today's Range$13.71▼$14.1350-Day Range$8.47▼$77.2852-Week Range$8.05▼$17.75Volume23,333 shsAverage Volume56,570 shsMarket Capitalization$79.91 millionP/E RatioN/ADividend YieldN/APrice Target$40.40 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media MediWound MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside194.2% Upside$40.40 Price TargetShort InterestHealthy0.58% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.56) to ($1.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector477th out of 1,049 stocksMedicinals & Botanicals Industry5th out of 15 stocks 3.5 Analyst's Opinion Consensus RatingMediWound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.40, MediWound has a forecasted upside of 194.2% from its current price of $13.73.Amount of Analyst CoverageMediWound has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.58% of the float of MediWound has been sold short.Short Interest Ratio / Days to CoverMediWound has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MediWound has recently decreased by 59.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMediWound does not currently pay a dividend.Dividend GrowthMediWound does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDWD. Previous Next 2.8 News and Social Media Coverage News SentimentMediWound has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MediWound this week, compared to 2 articles on an average week.Search Interest11 people have searched for MDWD on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added MediWound to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MediWound insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of MediWound is held by insiders.Percentage Held by InstitutionsOnly 13.58% of the stock of MediWound is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MediWound are expected to grow in the coming year, from ($2.56) to ($1.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MediWound is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MediWound is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About MediWound (NASDAQ:MDWD) StockMediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.Read More Receive MDWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter. Email Address MDWD Stock News HeadlinesJanuary 21, 2023 | americanbankingnews.comMediWound Ltd. (NASDAQ:MDWD) Receives Average Rating of "Moderate Buy" from BrokeragesJanuary 6, 2023 | finance.yahoo.comMediWound (NASDAQ:MDWD) investors are sitting on a loss of 61% if they invested five years agoJanuary 30, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 30, 2022 | finance.yahoo.comFDA Approves MediWound's NexoBrid For Burn TreatmentDecember 29, 2022 | finance.yahoo.comMediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in AdultsDecember 23, 2022 | finance.yahoo.comMediWound Expands NexoBrid’s Global Presence with Marketing Approval in JapanDecember 20, 2022 | finance.yahoo.comMediWound Strengthens European Presence of NexoBrid®December 19, 2022 | finance.yahoo.comMediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell CarcinomaJanuary 30, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 13, 2022 | finance.yahoo.comMediWound Expands Global Presence as NexoBrid® Gains Approval in IndiaDecember 5, 2022 | finance.yahoo.comMediWound Announces a 1-for-7 Reverse Share SplitDecember 2, 2022 | sg.finance.yahoo.comMediWound Reports Third Quarter 2022 Financial Results and Provides Company UpdateNovember 9, 2022 | finance.yahoo.comMediWound’s EscharEx Featured in Paper as a Potential Paradigm Shift Towards Non-Surgical Wound Bed Preparation in DFUsNovember 3, 2022 | finance.yahoo.comMediWound to Report Third Quarter 2022 Financial ResultsOctober 25, 2022 | finance.yahoo.comMediWound Announces Formation of Strategic Advisory BoardOctober 18, 2022 | globenewswire.comMediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022 - GlobeNewswireOctober 18, 2022 | finance.yahoo.comMediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022October 7, 2022 | globenewswire.comMediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings - GlobeNewswireOctober 7, 2022 | finance.yahoo.comMediWound Announces Closing of the Concurrent Registered Direct and Private Placement OfferingsSeptember 24, 2022 | marketwatch.comMediWound Shares Slide Premarket After Stock Offerings >MDWD - MarketWatchSeptember 23, 2022 | nasdaq.comHealth Care Sector Update for 09/22/2022: LLY, LUNA, ISRG, MDWD - NasdaqSeptember 22, 2022 | seekingalpha.comSpero, HeartBeam top healthcare gainers; MediWound, Vincerx lead losers' pack - Seeking AlphaSeptember 22, 2022 | benzinga.comWhy MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday’s Mid-Day Session - A - BenzingaSeptember 22, 2022 | benzinga.comVericel to Present at the Ladenburg Thalmann Healthcare Conference - Vericel (NASDAQ:VCEL) - BenzingaSeptember 22, 2022 | benzinga.comMediWound shares are trading lower after the company announced concurrent registered direct and private p - BenzingaSeptember 22, 2022 | globenewswire.comMediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million - GlobeNewswireSeptember 22, 2022 | finance.yahoo.comMediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 MillionSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MDWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter. Email Address MDWD Company Calendar Last Earnings11/15/2022Today1/30/2023Next Earnings (Estimated)3/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MDWD CUSIPN/A CIK1593984 Webwww.mediwound.com Phone972779714100Fax972-77-971-4111Employees77Year Founded2001Price Target and Rating Average Stock Price Forecast$40.40 High Stock Price Forecast$56.00 Low Stock Price Forecast$23.00 Forecasted Upside/Downside+194.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.7089) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,550,000.00 Net Margins-80.05% Pretax Margin-79.97% Return on EquityN/A Return on Assets-68.07% Debt Debt-to-Equity RatioN/A Current Ratio2.71 Quick Ratio2.50 Sales & Book Value Annual Sales$23.76 million Price / Sales3.36 Cash FlowN/A Price / Cash FlowN/A Book Value($1.18) per share Price / Book-11.64Miscellaneous Outstanding Shares5,820,000Free Float5,285,000Market Cap$79.91 million OptionableNot Optionable Beta0.99 Social Links Key ExecutivesOfer GonenChief Executive Officer & DirectorTzvi PalashChief Operating OfficerBoaz Gur-LavieChief Financial OfficerEty KlingerChief Research & Development OfficerRobert J. SnyderChief Medical OfficerKey CompetitorsBright GreenNASDAQ:BGXXHEXONYSE:HEXOValensNASDAQ:VLNSNatural Alternatives InternationalNASDAQ:NAIIUpexiNASDAQ:GRVIView All CompetitorsInsiders & InstitutionsEssex Investment Management Co. LLCBought 291,286 shares on 11/15/2022Ownership: 0.715%Armistice Capital LLCBought 1,915,520 shares on 11/14/2022Ownership: 5.780%Altium Capital Management LPBought 1,276,948 shares on 11/14/2022Ownership: 3.853%Renaissance Technologies LLCSold 48,381 shares on 11/14/2022Ownership: 1.289%Group One Trading L.P.Bought 9,200 shares on 11/9/2022Ownership: 0.000%View All Institutional Transactions MDWD Stock - Frequently Asked Questions Should I buy or sell MediWound stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDWD shares. View MDWD analyst ratings or view top-rated stocks. What is MediWound's stock price forecast for 2023? 6 brokerages have issued 12 month target prices for MediWound's shares. Their MDWD share price forecasts range from $23.00 to $56.00. On average, they predict the company's share price to reach $40.40 in the next year. This suggests a possible upside of 188.2% from the stock's current price. View analysts price targets for MDWD or view top-rated stocks among Wall Street analysts. How have MDWD shares performed in 2023? MediWound's stock was trading at $13.49 on January 1st, 2023. Since then, MDWD stock has increased by 3.9% and is now trading at $14.02. View the best growth stocks for 2023 here. Are investors shorting MediWound? MediWound saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 17,900 shares, a decrease of 59.0% from the December 31st total of 43,700 shares. Based on an average daily volume of 58,000 shares, the short-interest ratio is presently 0.3 days. Currently, 0.6% of the shares of the stock are sold short. View MediWound's Short Interest. When is MediWound's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023. View our MDWD earnings forecast. How were MediWound's earnings last quarter? MediWound Ltd. (NASDAQ:MDWD) released its quarterly earnings data on Tuesday, November, 15th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.21. The biopharmaceutical company earned $5.80 million during the quarter, compared to analysts' expectations of $4.65 million. When did MediWound's stock split? Shares of MediWound reverse split on the morning of Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What other stocks do shareholders of MediWound own? Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC). What is MediWound's stock symbol? MediWound trades on the NASDAQ under the ticker symbol "MDWD." Who are MediWound's major shareholders? MediWound's stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of MediWound? Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MediWound's stock price today? One share of MDWD stock can currently be purchased for approximately $14.02. How much money does MediWound make? MediWound (NASDAQ:MDWD) has a market capitalization of $81.60 million and generates $23.76 million in revenue each year. The biopharmaceutical company earns $-13,550,000.00 in net income (profit) each year or ($3.7089) on an earnings per share basis. How can I contact MediWound? MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The official website for the company is www.mediwound.com. The biopharmaceutical company can be reached via phone at 972779714100, via email at afields@lhai.com, or via fax at 972-77-971-4111. This page (NASDAQ:MDWD) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.